Duopharma Biotech Berhad, an investment holding company, researches, develops, manufactures, distributes, and imports pharmaceutical products and medicines in Malaysia and internationally. The company offers consumer healthcare products comprising vitamins and supplements, analgesics, eyecare, antacids, and skin care products; and generic drugs for various therapeutic classes, such as cardiovascular, dermatology, hormones, respiratory, sensory and nervous system, musculo-skeletal system, anti-infectives, and others. It also provides specialty pharmaceutical drugs for targeted conditions, biosimilar products, and medical devices and consumables to patients with conditions, such as diabetes, cancer, cardiovascular diseases, renal diseases, and others. The company's product portfolio comprises vascor, acetan, covasc, crystorvas, bezartan, vytan, and vytocor; insugen and basalog one; kytron, zuhera, lebreta, trevive, and krabeva; and unihepa, ranofer, erysaa, bi-haemosol, and haemosol. The company offers its products under the Champs, Flavettes, Eye Glo, Proviton, Naturalle, and Uphamol brands. In addition, it offers property management and services; and distributes, imports, and exports chemical products. The company was formerly known as CCM Duopharma Biotech Berhad and changed its name to Duopharma Biotech Berhad in February 2019. The company was founded in 1978 and is headquartered in Kuala Lumpur, Malaysia.
Duopharma Biotech Berhad Dividend Announcement
• Duopharma Biotech Berhad announced a semi annually dividend of RM0.01 per ordinary share which will be made payable on 2024-09-12. Ex dividend date: 2024-08-29
• Duopharma Biotech Berhad annual dividend for 2024 was RM0.03
• Duopharma Biotech Berhad annual dividend for 2023 was RM0.02
• Duopharma Biotech Berhad's trailing twelve-month (TTM) dividend yield is 2.3%
• Duopharma Biotech Berhad's payout ratio for the trailing twelve months (TTM) is 44.75%
• Duopharma Biotech Berhad's dividend growth over the last five years (2018-2023) was -21.05% year
• Duopharma Biotech Berhad's dividend growth over the last ten years (2013-2023) was -14.29% year
Duopharma Biotech Berhad Dividend History
Ex-Div date | Dividend amount | Dividend type | Pay date |
---|---|---|---|
2024-08-29 | RM0.01 | semi annually | 2024-09-12 |
2024-03-07 | RM0.02 | semi annually | |
2023-09-08 | RM0.01 | semi annually | 2023-09-22 |
2023-04-06 | RM0.02 | semi annually | 2023-05-09 |
2022-08-29 | RM0.01 | semi annually | 2022-09-14 |
2022-04-14 | RM0.02 | semi annually | 2022-05-13 |
2021-08-30 | RM0.01 | semi annually | 2021-09-15 |
2021-04-21 | RM0.06 | semi annually | 2021-05-21 |
2020-08-28 | RM0.01 | semi annually | 2020-09-11 |
2020-07-13 | RM0.05 | semi annually | 2020-08-12 |
2019-10-15 | RM0.01 | semi annually | 2019-11-14 |
2019-06-26 | RM0.04 | semi annually | 2019-07-26 |
2018-11-02 | RM0.01 | semi annually | 2018-11-23 |
2018-06-13 | RM0.06 | semi annually | 2018-07-17 |
2017-10-17 | RM0.03 | semi annually | 2017-11-10 |
2017-05-26 | RM0.04 | semi annually | 2017-06-23 |
2016-10-19 | RM0.03 | semi annually | |
2016-06-06 | RM0.06 | semi annually | |
2015-10-13 | RM0.04 | semi annually | |
2015-05-27 | RM0.11 | semi annually | |
2014-10-15 | RM0.03 | semi annually | |
2014-05-22 | RM0.10 | semi annually | |
2013-10-14 | RM0.03 | semi annually | |
2013-06-14 | RM0.08 | semi annually |
Duopharma Biotech Berhad Dividend per year
Duopharma Biotech Berhad Dividend growth
Duopharma Biotech Berhad Dividend Yield
Duopharma Biotech Berhad current trailing twelve-month (TTM) dividend yield is 2.3%. Interested in purchasing Duopharma Biotech Berhad stock? Use our calculator to estimate your expected dividend yield:
Duopharma Biotech Berhad Financial Ratios
Duopharma Biotech Berhad Dividend FAQ
Other factors to consider when evaluating Duopharma Biotech Berhad as a dividend stock include its dividend yield, dividend growth, payout ratio, and the sustainability of its dividend payments given its earnings and cash flow. These factors can provide insight into the company's ability to maintain or increase its dividend in the future.
Place an order: Use the brokerage's trading platform to place an order to buy Duopharma Biotech Berhad stock.
Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.
1. Determination of Dividend: Duopharma Biotech Berhad's board of directors reviews the company's financial performance, cash flow, future investment needs, and other relevant factors to determine the amount and timing of dividend payments.
2. Dividend Declaration: Once the board approves a dividend, Duopharma Biotech Berhad publicly announces the dividend amount, currency, and the ex-dividend date. The ex-dividend date is the date on or after which the buyer of the stock will not be eligible to receive the upcoming dividend payment.
3. Record Date: The record date is the date on which the company checks its records to identify shareholders who are eligible to receive the dividend. Only shareholders on record as of this date will receive the dividend.
4. Payment Date: On the designated payment date, Duopharma Biotech Berhad distributes the dividend to eligible shareholders. The dividend is usually paid in the form of cash directly into the shareholder's brokerage account or through other designated payment methods.
5. Tax Implications: Dividends received from Duopharma Biotech Berhad are generally taxable as income. Shareholders may need to report dividend income on their tax returns and pay applicable taxes according to their jurisdiction's tax regulations.
1. Record Date: Duopharma Biotech Berhad sets a record date, which is the date on which the company checks its records to determine the eligible shareholders. Only those who are shareholders on record as of this date will receive the dividend.
2. Payment Date: On the designated payment date, Duopharma Biotech Berhad distributes the dividend to eligible shareholders. The payment is usually made electronically, directly into the shareholder's brokerage account or bank account.
3. Currency: Duopharma Biotech Berhad declares the currency in which the dividend will be paid. Depending on the shareholder's location and the currency election made by the shareholder, the dividend will be converted to the appropriate currency during the payment process.
To assess the safety of Duopharma Biotech Berhad's dividend, it is crucial to analyze the company's financial health, debt levels, cash flow generation, and ability to sustain dividend payments over the long term. Additionally, monitoring the company's future earnings, cash flow projections, and management's commitment to dividend policies can provide valuable insights.
It is recommended to review Duopharma Biotech Berhad's financial reports, official announcements, and consult with financial advisors or experts who have access to the most current and comprehensive information about the company's financial situation.